Abstract |
Reaferon, the analog of human alpha 2-interferon obtained by gene engineering techniques, was studied with a view to its use for the prevention of hepatitis A. The study involved children of preschool age in Tashkent. In a strictly controlled trial children aged 2-6 years received the preparation orally in a dose of 1 X 10(6) I. U. or the diluent alone used as placebo. The preparation was administered to 1,100 children and the placebo to 1,078 children. The preparation and placebo were administered twice a week for two months. On the whole, during that period hepatitis A morbidity in both test and control groups of children was the same (5.1% and 4.9% respectively), but among children of nursery age receiving Reaferon the incidence of hepatitis A and acute respiratory viral infections was lower than among those receiving the placebo, though this difference was statistically significant only for cases of acute respiratory infections.
|
Authors | A K Iuldashev, A N Slepushkin, M A Khodzhaeva, E I Schastnyĭ, F Kh Kamilov |
Journal | Zhurnal mikrobiologii, epidemiologii i immunobiologii
(Zh Mikrobiol Epidemiol Immunobiol)
Issue 5
Pg. 65-9
(May 1988)
ISSN: 0372-9311 [Print] Russia (Federation) |
Vernacular Title | Izuchenie profilakticheskoĭ éffektivnosti reaferona pri virusnom gepatite A i ostrykh respiratornykh infektsiiakh u deteĭ. |
PMID | 2970744
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Interferon Type I
- Interferon alpha-2
- Interferon-alpha
- Placebos
- Recombinant Proteins
|
Topics |
- Acute Disease
- Child, Preschool
- Drug Evaluation
- Hepatitis A
(epidemiology, prevention & control)
- Humans
- Infant
- Interferon Type I
(therapeutic use)
- Interferon alpha-2
- Interferon-alpha
- Placebos
- Recombinant Proteins
(therapeutic use)
- Respiratory Tract Infections
(epidemiology, prevention & control)
- Seasons
- Time Factors
- Uzbekistan
|